Nephros Earnings Call Transcripts
Fiscal Year 2026
-
Record Q1 revenue of $5.2M was driven by 23% programmatic growth, offsetting lower emergency response sales. Gross margin fell to 57% due to tariffs, currency, and product mix, but margin improvement is expected as lower tariffs take effect.
Fiscal Year 2025
-
Revenue grew 33% to $18.8M in 2025 with net income of $1.2M, driven by programmatic sales and service expansion. Gross margin held at 62% for the year despite tariff pressures, and the company remains debt-free with $5.4M in cash.
-
Q3 2025 revenue rose 35% year-over-year to $4.8M, marking the fifth consecutive profitable quarter, with strong growth in programmatic and service revenue. New PFAS solutions and expansion into non-hospital verticals are expected to drive future growth.
-
Q2 2025 saw 36% revenue growth and the third straight quarter of profitability, driven by strong programmatic sales, new product launches, and expansion into non-healthcare verticals. Gross margin improved to 63%, and net income turned positive, with a growing cash balance and no debt.
Fiscal Year 2024
-
Q4 2024 saw 19% sales growth and a return to profitability, driven by core business expansion and new product launches. Gross margins improved, and the company ended the year debt-free with a strong cash position, setting the stage for growth in 2025.
-
Q3 2024 marked the first profitable quarter, with net income of $0.2M and gross margin rising to 61%. Revenue was $3.5M, up 8% sequentially but down 6% year-over-year, as cost controls and operational improvements offset programmatic declines.
-
Q2 2024 saw strong growth in core programmatic business and record customer sites, but total revenue declined 8% due to a sharp drop in emergency response sales. Gross margins remained robust, and net loss improved significantly year-over-year.